After Announcing a New CEO, UroGen Touts Positive Phase III Data for Urothelial Cancer

UroGen Pharma, based in New York, announced positive topline results from its Phase III OLYMPUS clinical trial. The trial evaluated UGN-101 (mitomycin gel) for instillation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC). Of the 71 patients in the trial, 61 have been evaluated for the primary endpoint, which was complete response. The remaining 10 patients are awaiting primary disease evaluation (PDE). On an intent-to-treat basis.
Read more...

;